We often treat medical biomarkers like a fuel gauge: a lower or higher reading is assumed to mean the same thing whether a vehicle is brand new or decades old. In progressive diseases, however, a biomarker behaves more like a weather report. The atmospheric signals that predict an impending storm are entirely different from the structural metrics used to map the aftermath.
A growing body of research demonstrates that biomarker sensitivity and predictive power are not static. Instead, they undergo profound handoffs as a disease evolves. Understanding why these diagnostic windows open and close requires looking at three distinct phenomena: biophysical transformations of the pathological target, cellular depletion and floor effects, and the accumulation of compensatory noise over a patient's lifespan.
Biophysical Handoffs and Changing Toxic Mechanisms
The primary biological drivers of a progressive condition frequently change over time. In protein-misfolding neurodegenerative diseases like Alzheimer's, for example, the physical nature of the toxic species evolves as the disease matures, altering the biochemical signals available for detection.
As shown by Suman De in Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression, soluble protein aggregates in cerebrospinal fluid change in both size and structural conformation over the course of the disease. Early-stage aggregates are small and hydrophobic, destroying brain cells by directly permeabilizing lipid bilayers. As these peptides grow into larger protofilaments, their toxic mechanism shifts. Suman De et al. demonstrated in Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms that these larger, late-stage structures cause damage primarily by triggering chronic inflammatory signaling through the brain's immune cells rather than through direct membrane leakage.
Early Stage Pathology Late Stage Pathology
[Small Soluble Oligomers] ---------> [Large Insoluble Protofilaments]
| |
v v
Direct Membrane Leakage Chronic Neuroinflammation
(High Soluble Marker Signal) (High Metabolic/Atrophy Signal)
This structural evolution creates a profound diagnostic handoff. Michael Ewers established in Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease that early cognitive decline is tightly coupled to the levels of soluble phosphorylated tau. However, once the disease reaches an advanced stage, cognitive decline becomes independent of these soluble precursors, driven instead by the self-sustaining accumulation of existing insoluble aggregates.
Consequently, causal models developed by Haoyang Zheng et al. in Data-driven causal model discovery and personalized prediction in Alzheimer's disease confirm that while initial protein accumulation triggers the pathological cascade, downstream neuronal loss and its associated feedback loops eventually take over as the dominant drivers of clinical decline. This is mirrored at the metabolic level: Tyler C. Hammond et al. demonstrated in β-amyloid and tau drive early Alzheimer’s disease decline while glucose hypometabolism drives late decline that protein pathologies drive early transitions, whereas glucose hypometabolism (impaired brain fuel use) becomes the primary engine of late-stage decline.
Cellular Depletion and the Floor Effect
Biomarkers also lose sensitivity due to the physical depletion of their pathological targets. If a diagnostic test measures active cellular destruction, its signal will naturally drop once the vulnerable cell population is exhausted or the disease state stabilizes.
In spinal muscular atrophy, Maren Freigang et al. observed in Biomarkers in 5q-associated spinal muscular atrophy—a narrative review that molecular markers of neurodegeneration, such as neurofilaments, lose their prognostic utility in adult populations. In infants, neurofilaments are highly sensitive because there is a massive, active pool of rapidly degenerating motor neurons. In adults, this pool has shrunk and the disease state has stabilized, meaning that high-sensitivity markers of acute damage must be replaced by alternative indicators to capture chronic disease activity.
A similar phenomenon occurs in structural imaging. Veronica Ravano et al. showed in Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis that microstructural white matter biomarkers are highly predictive during the early stages of multiple sclerosis. In advanced stages, however, widespread tissue atrophy and accumulated damage generate massive signal noise, obscuring the relationship between specific pathway integrity and clinical progression.
When local tissue hits a structural "floor effect," the diagnostic signal must be sought in entirely different anatomical structures. In glaucoma, Yueyin Pang et al. found in Contributions of Brain Microstructures and Metabolism to Visual Field Loss Patterns in Glaucoma Using Archetypal and Information Gain Analyses that traditional retinal measurements are highly effective for early detection but lose predictive power in advanced stages. To track late-stage neurodegeneration, clinicians must look downstream to brain-based structural and metabolic markers within the central visual pathways.
Compensatory Responses and Age-Related Noise
The human body is an active system that deploys compensatory mechanisms to mask or counteract damage. Over time, these responses alter the chemical and structural environment, directly impacting biomarker sensitivity.
In neurodevelopment, A. K. Srivastava et al. noted in Human genome meeting 2016 that the diagnostic accuracy of metabolic signatures for autism spectrum disorder peaks in early childhood and declines with age, suggesting that the body progressively compensates for early chemical imbalances over time. The timing of these compensatory responses can also reveal the nature of the underlying pathology. Yuek Ling Chai et al. showed in Plasma osteopontin as a biomarker of Alzheimer’s disease and vascular cognitive impairment that plasma osteopontin upregulates during the early stages of vascular impairment (likely responding to ischemic stress) but only appears in the late stages of Alzheimer's disease (potentially facilitating aggregate clearance).
As a disease progresses, the failure of these initial compensatory mechanisms can completely reshape the biochemical profile. Dan-ning Li et al. pointed out in Potential roles of oxidative distress on neurodegeneration in Parkinson's disease with neuropsychiatric symptoms that early-stage biochemical profiles do not generalize to advanced Parkinson's disease because new damage pathways emerge as defenses fail. This forces a shift in monitoring strategies: Mariasavina Severino et al. highlighted in Molecular connectivity studies in neurotransmission: a scoping review that the global dysregulation of secondary neurotransmitter systems often becomes a far more reliable indicator of late-stage cognitive decline than the primary system initially affected. Even standard clinical assays, such as the antineutrophil cytoplasmic antibody assays evaluated by Hiroshi Kurita et al. in Oral manifestations as an initial sign of Wegener's granulomatosis. Report of a Case and review of the literature., exhibit significant sensitivity fluctuations, dropping in localized or limited forms of pathology compared to active systemic cases.
Finally, the background noise of general systemic aging can completely obscure a biomarker's signal in older cohorts. Ming Ann Sim et al. demonstrated in Comparison of the additive value of blood-based and retinal biomarkers to clinical features in predicting cognitive decline that retinal imaging features predict cognitive decline effectively in mid-life, but lose their predictive power in older populations due to the cumulative noise of general microvascular aging.
This age-dependent context is so profound that the exact same biological metric can mean opposite things at different life stages. As Susan F Cheng et al. discovered in Rate of brain aging associates with future executive function in Asian children and older adults, an accelerated rate of "brain aging" relative to chronological age signals neurodegeneration in late adulthood, but reflects advanced, healthy maturation and superior cognitive control in children.
Key Foundational Work
Human genome meeting 2016 (2016) — contributed 2 concept elements to this direction.
Oral manifestations as an initial sign of Wegener's granulomatosis. Report of a Case and review of the literature. (1992) — contributed 1 concept elements to this direction.